Company Overview

Quanterix Corporation is a life sciences company specializing in ultra-sensitive biomarker detection technologies used primarily in neurology, oncology, cardiology, and infectious disease research and diagnostics. The company operates within the biotechnology and diagnostics industries, focusing on enabling earlier disease detection and more precise measurement of low-abundance proteins that are difficult to quantify using conventional immunoassays.

The company’s core offering is its proprietary Simoa® (Single Molecule Array) technology, which allows digital-level detection of proteins in blood and other biofluids. Quanterix primarily generates revenue through the sale of instruments, consumables, assay kits, and laboratory services to pharmaceutical and biotechnology companies, academic research institutions, and clinical laboratories. Founded in 2007, Quanterix emerged from academic research at Tufts University and has evolved from a research-focused platform provider into a commercial-stage diagnostics company with increasing clinical and regulated applications.

Business Operations

Quanterix operates through integrated business lines centered on its Simoa® platform, which includes automated analyzers, proprietary consumables, and validated assay kits. Revenue is generated through instrument placements, recurring consumables and reagents, and contract research services. The company also operates Quanterix Accelerator Laboratory, which provides biomarker testing services to pharmaceutical and biotechnology partners supporting drug development and clinical trials.

Operations span both domestic and international markets, with commercial activities in North America, Europe, and parts of Asia-Pacific. Quanterix controls proprietary assay development, digital immunoassay technologies, and cloud-enabled data analytics associated with its instruments. The company has historically expanded capabilities through acquisitions, including Aushon BioSystems, which enhanced its multiplex immunoassay and assay development expertise. Some aspects of recent corporate combinations in the spatial biology sector have been announced publicly, but full integration details remain data inconclusive based on available public sources.

Strategic Position & Investments

Quanterix’s strategy centers on expanding adoption of ultra-sensitive biomarkers in both research and clinical diagnostics, with particular emphasis on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Growth initiatives include menu expansion of validated assays, regulatory submissions for diagnostic use, and deeper integration with pharmaceutical clinical development workflows.

The company has invested heavily in assay development, automation, and software-enabled data interpretation. Strategic investments and transactions have targeted complementary biomarker and tissue-based technologies, although certain announced mergers or combinations remain subject to regulatory approval and final closing terms, making some forward-looking impacts data inconclusive based on available public sources. Emerging focus areas include blood-based neurological diagnostics and translational biomarkers for precision medicine.

Geographic Footprint

Quanterix is headquartered in North America (United States), with its principal offices and laboratories located in Massachusetts. The company maintains a direct commercial presence in Europe and distributes products across Asia-Pacific, supported by a combination of direct sales teams and regional distributors.

International operations contribute meaningfully to revenue, particularly in European pharmaceutical research markets. Quanterix’s technology is used globally in clinical research trials and academic laboratories, giving the company international influence in biomarker standardization and translational research despite a relatively concentrated physical footprint.

Leadership & Governance

Quanterix was founded by David R. Walt, whose academic research underpins the Simoa® technology and who continues to influence the company’s scientific direction. The leadership team emphasizes innovation, clinical translation, and long-term adoption of biomarker-driven diagnostics.

Key executives include:

• Masoud Toloue – President & Chief Executive Officer
• Dhaval Patel – Chief Financial Officer
• Goran Emdin – Chief Technology Officer
• Kevin Hrusovsky – Executive Chairman
• Lyndon McGonigle – Chief Commercial Officer

The leadership philosophy centers on leveraging proprietary technology to shift diagnostics toward earlier, less invasive detection, while maintaining disciplined investment aligned with regulatory and clinical validation milestones.